Daiichi Sankyo is a Japanese pharmaceutical company that operates in the large pharma sector. The company is committed to providing innovative and effective healthcare solutions to patients around the world. Daiichi Sankyo has a strong presence in Japan and has expanded its operations globally, with a focus on developing and marketing drugs for cardiovascular disease, oncology, and other therapeutic areas.

In recent years, Daiichi Sankyo has been actively pursuing decarbonisation and implementing measures to reduce its carbon footprint. The company has set ambitious targets to reduce its greenhouse gas emissions and has implemented a range of initiatives to achieve these goals. One of the key areas of focus for Daiichi Sankyo is corporate energy management, which involves improving energy efficiency and reducing energy consumption across its operations.

To achieve its energy management goals, Daiichi Sankyo has implemented a range of measures, including the use of renewable energy sources such as solar and wind power. The company has also invested in energy-efficient technologies and has implemented energy-saving measures such as the installation of LED lighting and the use of energy-efficient HVAC systems.

In addition to these measures, Daiichi Sankyo has also implemented corporate power purchase agreements (PPAs) to support the development of renewable energy projects. PPAs are long-term contracts between a company and a renewable energy provider, which allow the company to purchase renewable energy at a fixed price. By entering into these agreements, Daiichi Sankyo is able to support the development of renewable energy projects and reduce its reliance on fossil fuels.

Daiichi Sankyo has set a target to reduce its greenhouse gas emissions by 30% by 2030, compared to its 2017 baseline. The company is also committed to achieving carbon neutrality by 2050. To achieve these goals, Daiichi Sankyo is implementing a range of measures, including the use of renewable energy sources, the implementation of energy-efficient technologies, and the development of new products and services that support decarbonisation.

In addition to its efforts to reduce its carbon footprint, Daiichi Sankyo is also committed to promoting sustainability across its operations. The company has implemented a range of initiatives to reduce waste and improve resource efficiency, including the use of sustainable packaging materials and the implementation of recycling programs.

Daiichi Sankyo is also committed to promoting sustainability across its supply chain. The company works closely with its suppliers to ensure that they meet its sustainability standards and has implemented a range of measures to promote sustainable sourcing practices.

Overall, Daiichi Sankyo is a leading pharmaceutical company that is committed to promoting sustainability and decarbonisation. The company has set ambitious targets to reduce its carbon footprint and is implementing a range of measures to achieve these goals. By promoting renewable energy, energy efficiency, and sustainable practices across its operations and supply chain, Daiichi Sankyo is playing a key role in promoting a more sustainable future.